HYFTOR

This brand name is authorized in Austria, Estonia, Ireland, Italy, Lithuania, United States

Active ingredients

The drug HYFTOR contains one active pharmaceutical ingredient (API):

1 Sirolimus UNII W36ZG6FT64 - SIROLIMUS

Sirolimus inhibits T-cell activation induced by most stimuli, by blocking calcium-dependent and calcium-independent intracellular signal transduction. Studies demonstrated that its effects are mediated by a mechanism that is different from that of ciclosporin, tacrolimus, and other immunosuppressive agents. Read about Sirolimus

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
HYFTOR Gel	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L04AH01	Sirolimus	L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AH Mammalian target of rapamycin (mTOR) kinase inhibitors
Discover more medicines within L04AH01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 3044876
Country: IT	Agenzia del Farmaco	Identifier(s): 050701010
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1097168
Country: US	FDA, National Drug Code	Identifier(s): 73683-101